2018
Speed of Adoption of Immune Checkpoint Inhibitors of Programmed Cell Death 1 Protein and Comparison of Patient Ages in Clinical Practice vs Pivotal Clinical Trials
O’Connor J, Fessele KL, Steiner J, Seidl-Rathkopf K, Carson KR, Nussbaum NC, Yin ES, Adelson KB, Presley CJ, Chiang AC, Ross JS, Abernethy AP, Gross CP. Speed of Adoption of Immune Checkpoint Inhibitors of Programmed Cell Death 1 Protein and Comparison of Patient Ages in Clinical Practice vs Pivotal Clinical Trials. JAMA Oncology 2018, 4: e180798-e180798. PMID: 29800974, PMCID: PMC6143052, DOI: 10.1001/jamaoncol.2018.0798.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntibodies, Monoclonal, HumanizedCarcinoma, Non-Small-Cell LungCarcinoma, Renal CellClinical Trials as TopicFemaleFollow-Up StudiesHumansKidney NeoplasmsLung NeoplasmsMaleMiddle AgedNivolumabPractice Patterns, Physicians'PrognosisProgrammed Cell Death 1 ReceptorRetrospective StudiesConceptsNon-small cell lung cancerPivotal clinical trialsRenal cell carcinomaCell death 1 proteinEligible patientsImmune checkpoint inhibitorsDeath 1 proteinClinical trialsClinical practiceFDA approvalAgent treatmentCheckpoint inhibitorsAnti-PD-1 agentsFlatiron Health networkRetrospective cohort studyAge of patientsCell lung cancerClinical trial participantsCohort studyPatient ageYounger patientsMore patientsSuch patientsTrial evidenceCell carcinoma
2017
Does coaching goals of care discussion skills make a difference?
Bickell N, Adelson K, Gonsky J, Pintova S, Levy B, Lin J, Franco R, Egorova N, Smith C. Does coaching goals of care discussion skills make a difference? Journal Of Clinical Oncology 2017, 35: 6586-6586. DOI: 10.1200/jco.2017.35.15_suppl.6586.Peer-Reviewed Original ResearchAdvanced cancer patientsGOC discussionsCancer patientsCancer prognosisClarity of valuesPoor health literacyQuality of lifeElicit patient valuesEligible patientsIntervention patientsYear prognosisMean ageCare discussionsIntervention groupPatient reportsPatient understandingTreatment goalsHealth literacyDisease processPatientsSide effectsPatient valuesOncologists' communication skillsCommunication skills trainingPrognosisDevelopment of a complex patient identification process for the CMS’ Oncology Care Model.
Sinanis N, Abdelghany O, Strait M, Lyons C, Adelson K. Development of a complex patient identification process for the CMS’ Oncology Care Model. Journal Of Clinical Oncology 2017, 35: 32-32. DOI: 10.1200/jco.2017.35.8_suppl.32.Peer-Reviewed Original ResearchOncology Care ModelD statusCare modelOral drugsPatient identification processesLast visit dateMedicare Part DEligible patientsEnhanced paymentsOral prescriptionDrug fillsVisit dateSpecialty pharmacyEligibility criteriaPatientsCare managementMedicare Part BPatient identificationNew prescriptionsMedicare Part B.DrugsPrescriptionPart DStepwise approachInsurance informationAn EPIC electronic decision support tool to identify percentage of patients with stage IV thoracic or gastrointestinal malignancy who would benefit from concurrent palliative care but do not currently receive it.
Adelson K, Trant A, Framski K, Swidler M, Kashyap N. An EPIC electronic decision support tool to identify percentage of patients with stage IV thoracic or gastrointestinal malignancy who would benefit from concurrent palliative care but do not currently receive it. Journal Of Clinical Oncology 2017, 35: 133-133. DOI: 10.1200/jco.2017.35.8_suppl.133.Peer-Reviewed Original ResearchEpic electronic health recordConcurrent palliative carePalliative careOncologic careElectronic decision support toolPalliative care visitsPC referral rateSmilow Cancer HospitalStandard oncologic careYale-New HavenPalliative care consultStage IV diseasePercentage of patientsPalliative care servicesHealth care utilizationICD-10 diagnosisQuality of lifeVolume of patientsElectronic health recordsAlign careCare consultEligible patientsPC referralEnd of lifeIOM guidelines
2016
An electronic intervention to improve structured cancer stage data capture.
Adelson K, Framski K, Lazette P, Vega T, Lilenbaum R. An electronic intervention to improve structured cancer stage data capture. Journal Of Clinical Oncology 2016, 34: 151-151. DOI: 10.1200/jco.2016.34.7_suppl.151.Peer-Reviewed Original ResearchTumor RegistryCancer stagingOutcome analysisClinical trial eligibility determinationDisease-free intervalPalliative care consultationClinical trial eligibilityNumber of patientsElectronic decision supportEligible patientsTrial eligibilityAdvanced diseaseOverall survivalCare consultationsCancer CommitteeFree intervalCancer stageClinical trialsLung measuresClinical notesPatientsRegistry reportingStagingCancerElectronic intervention
2011
OT3-01-01: Randomized Phase II Study of Fulvestrant Versus Fulvestrant Plus Bortezomib in Postmenopausal Women with Estrogen Receptor (ER) Positive, Aromatase-Inhibitor (AI) Resistant Metastatic Breast Cancer (MBC): New York Cancer Consortium Trial P8457.
Adelson K, Raptis G, Sparano J, Germain D. OT3-01-01: Randomized Phase II Study of Fulvestrant Versus Fulvestrant Plus Bortezomib in Postmenopausal Women with Estrogen Receptor (ER) Positive, Aromatase-Inhibitor (AI) Resistant Metastatic Breast Cancer (MBC): New York Cancer Consortium Trial P8457. Cancer Research 2011, 71: ot3-01-01-ot3-01-01. DOI: 10.1158/0008-5472.sabcs11-ot3-01-01.Peer-Reviewed Original ResearchMedian progression-free survivalMetastatic breast cancerProgression-free survivalAI therapyPostmenopausal womenMetastatic diseaseAI-resistant metastatic breast cancerResistant metastatic breast cancerAdjuvant AI therapyAI-resistant diseaseClinical benefit ratePrior chemotherapy regimenPhase II studyAdverse event ratesAddition of bortezomibHuman breast cancer cell linesEstrogen-receptor positiveRandomized phase II designsBreast cancer cell linesPhase II designUnfolded protein responseChemotherapy regimenEligible patientsMeasurable diseasePrior chemotherapy